Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 703

1.
2.

A randomized trial of accelerated hyperfractionated radiation therapy and bis-chloroethyl nitrosourea for malignant glioma. A preliminary report of Radiation Therapy Oncology Group 83-02.

Curran WJ Jr, Scott CB, Nelson JS, Weinstein AS, Phillips TL, Murray K, Fischbach AJ, Yakar D, Schwade JG, Powlis WD, et al.

Cancer. 1992 Dec 15;70(12):2909-17.

3.

Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302.

Nelson DF, Curran WJ Jr, Scott C, Nelson JS, Weinstein AS, Ahmad K, Constine LS, Murray K, Powlis WD, Mohiuddin M, et al.

Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):193-207.

PMID:
8380567
4.
6.

Accelerated hyperfractionated radiation therapy for malignant glioma. A phase II study.

Jeremic B, Grujicic D, Antunovic V, Djuric L, Shibamoto Y.

Am J Clin Oncol. 1995 Oct;18(5):449-53.

PMID:
7572767
7.

Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.

Valentini V, Morganti AG, Gambacorta MA, Mohiuddin M, Doglietto GB, Coco C, De Paoli A, Rossi C, Di Russo A, Valvo F, Bolzicco G, Dalla Palma M; Study Group for Therapies of Rectal Malignancies (STORM)..

Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1129-39. Epub 2006 Jan 18.

PMID:
16414206
8.

High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients.

Durando X, Lemaire JJ, Tortochaux J, Van-Praagh I, Kwiatkowski F, Vincent C, Bailly C, Verrelle P, Irthum B, Chazal J, Bay JO.

Bone Marrow Transplant. 2003 Apr;31(7):559-64.

PMID:
12692621
9.

Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 83-02.

Murray KJ, Nelson DF, Scott C, Fischbach AJ, Porter A, Farnan N, Curran WJ Jr.

Int J Radiat Oncol Biol Phys. 1995 Feb 1;31(3):453-9.

PMID:
7852106
10.

Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol.

Souhami L, Seiferheld W, Brachman D, Podgorsak EB, Werner-Wasik M, Lustig R, Schultz CJ, Sause W, Okunieff P, Buckner J, Zamorano L, Mehta MP, Curran WJ Jr.

Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):853-60.

PMID:
15465203
11.
12.

Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors.

Prados MD, Larson DA, Lamborn K, McDermott MW, Sneed PK, Wara WM, Chang SM, Mack EE, Krouwer HG, Chandler KL, Warnick RE, Davis RL, Rabbitt JE, Malec M, Levin VA, Gutin PH, Phillips TL, Wilson CB.

Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):57-63.

PMID:
9422558
13.

Phase II radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme.

Langer CJ, Ruffer J, Rhodes H, Paulus R, Murray K, Movsas B, Curran W.

Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):113-9.

PMID:
11516860
14.

Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials.

Buckner JC, Ballman KV, Michalak JC, Burton GV, Cascino TL, Schomberg PJ, Hawkins RB, Scheithauer BW, Sandler HM, Marks RS, O'Fallon JR; North Central Cancer Treatment Group 93-72-52.; Southwest Oncology Group 9503 Trials..

J Clin Oncol. 2006 Aug 20;24(24):3871-9.

PMID:
16921039
15.

Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.

Bradley J, Graham MV, Winter K, Purdy JA, Komaki R, Roa WH, Ryu JK, Bosch W, Emami B.

Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):318-28.

PMID:
15667949
16.

A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104.

Murray KJ, Scott C, Greenberg HM, Emami B, Seider M, Vora NL, Olson C, Whitton A, Movsas B, Curran W.

Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):571-4.

PMID:
9336134
17.

Accelerated hyperfractionated radiotherapy in supratentorial malignant astrocytomas.

Genc M, Zorlu AF, Atahan IL.

Radiother Oncol. 2000 Aug;56(2):233-8.

PMID:
10927143
19.

Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: combined X-ray radiotherapy, chemotherapy, and carbon ion radiotherapy.

Mizoe JE, Tsujii H, Hasegawa A, Yanagi T, Takagi R, Kamada T, Tsuji H, Takakura K; Organizing Committee of the Central Nervous System Tumor Working Group..

Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):390-6. Epub 2007 Apr 24.

PMID:
17459607
20.

Supplemental Content

Support Center